{"entity":{"id":"crc01","kind":"drug","name":"CRC01","aka":[],"tldr":"CRC01 is an experimental CAR-T cell therapy from Curocell in phase 2 trials for diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia, aimed at CD19.","summary":"CRC01 is a CAR-T cell therapy developed by Curocell. Its target is CD19 (the sponsor names CD19). The sponsor states: A single intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells directed against CD19, engineered with PD-1 and TIGIT knock-down to enhance T-cell effector function, given after fludarabine/cyclophosphamide conditioning. ClinicalTrials.gov describes the intervention as: Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-t. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. The largest, NCT04836507, plans to enrol 91 participants with primary completion expected 2030-08-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of CRC01","url":"https://clinicaltrials.gov/search?intr=CRC01"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","follicular-lymphoma","all-leukemia"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04836507"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"A single intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells directed against CD19, engineered with PD-1 and TIGIT knock-down to enhance T-cell effector function, given after fludarabine/cyclophosphamide conditioning.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/crc01/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"trial":[{"id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/"}],"paper":[{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/"}]}}